title: Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?
abstract: Chemotherapy-induced cardiotoxicity, is a well-known and potentially serious complication strongly impacting the quality of life and overall survival of breast cancer patients. The current diagnostic approach to detect cardiac damage is the estimation of left ventricular ejection fraction by echocardiography. However, this approach exhibits less sensitivity toward early prediction of cardiomyopathy, not allowing for preventive strategies. Measurement of serum cardiac-specific biomarkers can be a valid diagnostic tool for identifying patients prone to developing cardiotoxocity and in whom closer cardiac monitoring and preventive strategies are pivotal. In this article, we review work done on biomarkers in recent years, with an emphasis on troponin and B-type natriuretic peptide, which are currently the most studied in this field. We also briefly discuss current and emerging imaging techniques for early detection of cardiomyopathy.
authors: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-3721, USA.
authors: Misbat
authors: M
authors: Chaudry
authors: Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Jose
authors: J
authors: Banchs
authors: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-3721, USA.|Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors: Mariana
authors: M
authors: Chavez-MacGregor
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects*; D015415:Biomarkers / Q000378:metabolism*; D066126:Cardiotoxicity / Q000473:pathology*; D006801:Humans; D000068878:Trastuzumab / Q000009:adverse effects*
chemical_list: D018943:Anthracyclines; D015415:Biomarkers; D000068878:Trastuzumab
keywords: anthracycline; biomarkers; breast cancer; cardiotoxicity; trastuzumab